Midocalm, 150 mg 30 pcs.

Midocalm is a myorelaxant of central action.

It reduces pathologically increased muscle tone, muscle stiffness, improves voluntary active movements.

The mechanism of action is associated with the regulatory effect on the caudal part of the reticular formation, suppression of pathologically elevated spinal reflex activity, action on the peripheral nerve endings.

Indications

treatment of pathologically increased muscle tone and spasms of striated muscles resulting from organic diseases of the central nervous system (damage to the pyramidal tracts, multiple sclerosis, cerebral stroke, myelopathy, encephalomyelitis);
treatment of increased tone and muscle spasms, muscle contractures accompanying diseases of the movement organs (including spondylosis, spondyloarthrosis, cervical and lumbar syndromes, arthrosis of large joints);
rehabilitation treatment after orthopedic and traumatological operations;
as part of combination therapy of obliterating vascular diseases (obliterating atherosclerosis, diabetic angiopathy, thromboangiitis obliterans, Raynaud’s disease, diffuse scleroderma), diseases arising from a disorder of vascular innervation (acrocyanosis, intermittent angioedema);
Little’s disease (infantile cerebral palsy) and other encephalopathies accompanied by muscular dystonia.

Pharmacological effect

Mydocalm is a centrally acting muscle relaxant.

Reduces pathologically increased muscle tone, muscle rigidity, improves voluntary active movements.

The mechanism of action is associated with a regulatory effect on the caudal part of the reticular formation, suppression of pathologically increased spinal reflex activity, and effects on peripheral nerve endings.

Special instructions

Use strictly as prescribed by your doctor to avoid complications.

Impact on the ability to drive vehicles and machinery.

No studies have been conducted, but no such information has been reported over many years of use of the drug.

Active ingredient

Tolperisone

Composition

1 tablet contains:

Active substances:

tolperisone hydrochloride 150 mg,

Excipients:

lactose,

citric acid monohydrate,

colloidal silicon anhydrous,

stearin,

talc,

microcrystalline cellulose,

corn starch,

titanium dioxide (E171),

dye (E129 or E172).

Film casing:

colloidal silicon dioxide;

titanium dioxide (E171 – 77891);

lactose monohydrate;

macrogol 6000;

hypromellose

Pregnancy

The drug Mydocalm is contraindicated during pregnancy, breastfeeding and children under 3 years of age.

Contraindications

hypersensitivity to any of the components of the drug;
myasthenia gravis.

Side Effects

drowsiness,
nausea,
dizziness
dry mouth,
constipation,
diarrhea,
pressure reduction
feeling tired
sleep disorders,
confusion.

Interaction

There are no data on interactions that limit the use of Mydocalm.

Although tolperisone has an effect on the central nervous system, it does not cause a sedative effect, so it can be used in combination with sedatives, hypnotics and drugs containing alcohol.

Does not affect the effect of alcohol on the central nervous system.

Tolperisone enhances the effect of niflumic acid; when using these drugs simultaneously, it may be necessary to reduce the dose of niflumic acid.

General anesthesia, peripheral muscle relaxants, psychotropic drugs, clonidine – enhance the effect of tolperisone.

Overdose

There have been no reports of overdose with Mydocalm.

Storage conditions

In a dry place, at a temperature of 15–30 °C

Shelf life

3 years

Manufacturer

Gedeon Richter-Rus/Gedeon Richter, Russia